Skip to main content
SpringerLink
Log in

Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors

  • Chapter
Biological and Hormonal Therapies of Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 94))

Abstract

Postmenopausal women often experience annoying and sometimes debilitating menopausal symptoms, and breast cancer survivors are no exception. Hot flashes, dyspareunia, atrophic vaginitis with attendant urinary tract symptoms, sleep disturbance, and mood change are among these symptoms. Estrogen replacement therapy (ERT) has been shown to ameliorate these problems [1,2], and as informed consumers, breast cancer survivors are increasingly inquiring about and/or requesting ERT.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American College of Obstetricians and Gynecologists. 1992. Hormone Replacement Therapy. Washington, DC: ACOG Technical Bulletin, April, no.166.

    Google Scholar 

  2. Wiklund I, Holst J, Karlberg J, et al. 1992. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 14:211–224.

    PubMed  CAS  Google Scholar 

  3. Grady D, Rubin SM, Petitti DB, et al. 1992. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 15:1016–1037.

    Google Scholar 

  4. Barrett-Connor E, Bush TL. 1991. Estrogen and coronary heart disease in women. Clin Cardiol 265:1861–1867.

    CAS  Google Scholar 

  5. Editorial. 1990. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 75 (Suppl 4):18S–25S.

    Google Scholar 

  6. Kiel DP, Felson DT, Anderson JJ, et al. 1987. Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 317:1169–1174.

    PubMed  CAS  Google Scholar 

  7. Miller BA, Feuer EJ, Hankey BF, et al. 1993. Recent incidence trends for breast cancer in women and the relevance of early detection: an update. Cancer 43:27–41.

    CAS  Google Scholar 

  8. Fisher B, Costantino J, Redmond C, et al. 1989. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogenreceptor-positive tumors. N Engl J Med 320:479–484.

    PubMed  CAS  Google Scholar 

  9. Mansour EG, Gray R, Shatila AH, et al. 1989. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med 320:485–490.

    PubMed  CAS  Google Scholar 

  10. The Ludwig Breast Cancer Study Group. 1989. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320:491–496.

    Google Scholar 

  11. Fisher B, Redmond C, Dimitrov NV, et al. 1989. A randomized trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320:474–478.

    Google Scholar 

  12. Bines J, Oleske DM, Cobleigh MA. 1996. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718–1729.

    PubMed  CAS  Google Scholar 

  13. Mehta RR, Beattie CW, Das Gupta. 1991. Endocrine profile in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 20:125–132.

    CAS  Google Scholar 

  14. Bonadonna G, Valagussa P, Rossi A, et al. 1979. CMF adjuvant chemotherapy in operable breast cancer. In Jones SE, Salmon SS, eds. Adjuvant Therapy of Cancer II. New York: Grune and Stratton, pp. 227–235.

    Google Scholar 

  15. Stampfer MJ, Colditz GA, Willett WC, et al. 1991. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses’ Health Study. N Engl J Med 325:756–762.

    PubMed  CAS  Google Scholar 

  16. Rosen PP, Groshen S, Kinne DW, et al. 1993. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1NOMO/T2NOMO patients with long-term follow-up. J Clin Oncol 11:2090–2100.

    PubMed  CAS  Google Scholar 

  17. Merill JM. 1992. Questions and answers. Estrogen replacement therapy after breast cancer. JAMA 267:568.

    Google Scholar 

  18. Creasman WT. 1991. Estrogen replacement therapy: is previously treated cancer a contraindication? Obstet Gynecol 77:308–311.

    PubMed  CAS  Google Scholar 

  19. Hutchinson-Williams KA, et al. 1991. Yale J Biol Med 64:607–626.

    PubMed  CAS  Google Scholar 

  20. Theriault RL, Sellin RV. 1991. A clinical dilemma: estrogen replacement therapy in postmenopausal women with a background of primary breast cancer. Ann Oncol 2:709–717.

    PubMed  CAS  Google Scholar 

  21. Davidson JA. 1991. The need for a randomized trial of hormone replacement therapy in women with breast cancer. Med J Aust 157:429.

    Google Scholar 

  22. DiSaia PJ. 1984. Invited discussion. Am J Obstet Gynecol 150:129.

    Google Scholar 

  23. Henderson IC. 1993. Risk factors for development of breast cancer. Cancer (Suppl) 71:2127–2140.

    PubMed  CAS  Google Scholar 

  24. Eden JA. 1992. General practice, common problems: oestrogen and the breast. 1. Myths about oestrogen and breast cancer. Med J Aust 157:175–176.

    PubMed  CAS  Google Scholar 

  25. Stoll BA, Parbhoo S. 1988. Treatment of menopausal symptoms in breast cancer patients. Lancet 1(8597):1278–1279.

    PubMed  CAS  Google Scholar 

  26. Marchant DJ. 1993. Estrogen-replacement therapy after breast cancer. Cancer 71:2169–2176.

    PubMed  CAS  Google Scholar 

  27. Eden J. 1992. General practice, common problems: oestrogen and the breast. 2. The management of the menopausal woman with breast cancer. Med J Aust 157:247–250.

    PubMed  CAS  Google Scholar 

  28. Stoll A. 1989. Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 25:1909.

    PubMed  CAS  Google Scholar 

  29. American College of Physicians. 1992. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 117:1038–1041.

    Google Scholar 

  30. Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M. 1993. Cardiovascular disease in women. Circulation 88:1900–2009.

    Google Scholar 

  31. Early Breast Cancer Trialists’ Collaborative Group. 1992. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1–15.

    Google Scholar 

  32. Powles TJ. 1990. Tamoxifen and oestrogen replacement. Lancet 336(8706):48.

    Google Scholar 

  33. Ernster VL, Wrensch MR, Petrakis NL, King EB, Miike R, Mural J, Goodson WH III, Siiteri PK. 1987. Benign and malignant breast disease: initial study results of serum and breast fluid analyses of endogenous estrogens. J Natl Cancer Inst 79:949–960.

    PubMed  CAS  Google Scholar 

  34. Jordan VC, Fritz NF, Tormey DC. 1987. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 47:624–630.

    PubMed  CAS  Google Scholar 

  35. Powles TJ, Hardy JR, Ashley SE, et al. 1989. Chemo-prevention of breast cancer. Breast Cancer Res Treat 14:23–31.

    PubMed  CAS  Google Scholar 

  36. Sherman BM, Chapler FK, Crickard K, et al. 1979. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 64:398–404.

    PubMed  CAS  Google Scholar 

  37. Sunderland MC, Osborne CK. 1991. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 9:1283–1297.

    PubMed  CAS  Google Scholar 

  38. Pollack M, Polychronakos C, Blauer S, et al. 1990. Effect of tamoxifen on serum insulin-like growth factor I (IGF-I) levels of stae I breast cancer patients. Proc Annu Meet Am Soc Clin Oncol 9:A70.

    Google Scholar 

  39. Vignon F, Bouton M-M, Rochefort H. 1987. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun 146:1502–1508.

    PubMed  CAS  Google Scholar 

  40. O’Brien CA, Liskamp RM, Solomon DH, et al. 1985. Inhibition of protein kinase C by tamoxifen. Cancer Res 45:2462–2465.

    Google Scholar 

  41. Lam H-YP. 1984. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 118:27–32.

    PubMed  CAS  Google Scholar 

  42. Hug V, Hortobagyi GN, Drewinka B, et al. 1985. Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol 3:1672–1677.

    PubMed  CAS  Google Scholar 

  43. Mandeville R, Ghali SS, Chausseau J-P. 1984. In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen). Eur J Cancer Clin Oncol 20:983–985.

    PubMed  CAS  Google Scholar 

  44. Heuson JC. 1976. Current overview of EORTC clinical trials with tamoxifen. Cancer Treat Rep 60:1463–1466.

    PubMed  CAS  Google Scholar 

  45. Manni A, Pearson OH. 1980. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64:779–785.

    PubMed  CAS  Google Scholar 

  46. Sawka CA, Pritchard KI, Paterson AHG, et al. 1986. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res 46:3152–3156.

    PubMed  CAS  Google Scholar 

  47. Pritchard KI, Thomson DB, Myers RE, et al. 1980. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64:787–796.

    PubMed  CAS  Google Scholar 

  48. Wada T, Koyama H, Terasawa T. 1981. Effect of tamoxifen in premenopausal Japanese women with advanced breast cancer. Cancer Treat Rep 65:728–729.

    PubMed  CAS  Google Scholar 

  49. Yoshida M, Murai H, Miura S. 1982. Tamoxifen therapy for premenopausal and postmenopausal Japanese females with advanced breast cancer. Jpn J Clin Oncol 12:57–64.

    Google Scholar 

  50. Hoogstraten B, Fletcher WS, Grad-el-Mawia N, et al. 1982. Tamoxifen and oophorectomy in the treatment of recurrent breast cancer. A Southwest Oncology Group study. Cancer Res 42:4788–4791.

    PubMed  CAS  Google Scholar 

  51. Hoogstraten B, Gad-el-Mawla N, Maloney TR, et al. 1984. Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study. Cancer 54:2248–2256.

    PubMed  CAS  Google Scholar 

  52. Margrieter R, Wiegele J. 1984. Tamoxifen for premenopausal patients with advanced breast cancer. Cancer Res Treat 4:45–49.

    Google Scholar 

  53. Planting AST, Alexieva-Figusch J, Blonk-v.d. Wijst J, et al. 1985. Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer Treat Rep 69:363–368.

    PubMed  CAS  Google Scholar 

  54. Krywicki RF, Yee D. 1992. The insulin-like growth family family of ligands, receptors and binding proteins. Breast Cancer Res Treat 22:7–19.

    PubMed  CAS  Google Scholar 

  55. Peyrat JP, Bonneterre J. 1992. Type I IGF receptor in human breast diseases. Breast Cancer Res Treat 22:59–67.

    PubMed  CAS  Google Scholar 

  56. Pollak MN, Polychronakos C, Yousefi S, et al. 1988. Characterization of insulin-like growth factor (IGF-1) receptors of human breast cancer cells. Biochem Biophys Res Commun 154:326–331.

    PubMed  CAS  Google Scholar 

  57. Thorsen T, Lahooti H, Rasmussen M, et al. 1992. Oestradiol treatment increases the sensitivity of MCF-7 cells for the growth stimulatory effect of IGF-I. J Steroid Biochem Mol Biol 41:537–540.

    PubMed  CAS  Google Scholar 

  58. Vignon F, Bouton MM, Rochefort H. 1987. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun 146:1502–1508.

    PubMed  CAS  Google Scholar 

  59. Friedl A, Jordan VC, Pollak M. 1993. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 29A(10):1368–1372.

    PubMed  CAS  Google Scholar 

  60. Goldberg RM, Loprinzi CL, O’Fallon JR, Veeder MH, Miser AW, Mailliard JA, Michalak JC, Dose A, Rowland KM, Burnham NL. 1994. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 12:155–158.

    PubMed  CAS  Google Scholar 

  61. Nesheim BI, Saetre T. 1981. Reduction of menopausal hot flushes by methyldopa. Eur J Clin Pharmacol 20:413–416.

    PubMed  CAS  Google Scholar 

  62. Erik Y, Meldrum DR, Lagasse LD, Judd HL. 1981. Effect of megestrol acetate on flushing and bone metabolism in postmenopausal women. Maturitas 3:167–172.

    Google Scholar 

  63. Loprinzi CL, Michalak JC, Quella SK, et al. 1994. Megestrol acetate for the prevention of hot flashes. N Engl J Med 331:347–352.

    PubMed  CAS  Google Scholar 

  64. Bullock JL, Massey FM, Cambrell RD Jr. 1975. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 46:165–168.

    PubMed  CAS  Google Scholar 

  65. Morrison JC, Martin DC, Blair RA, et al. 1980. The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 138:99–104.

    PubMed  CAS  Google Scholar 

  66. Albrecht BG, Schiff I, Tulchinsky D, Ryan KJ. 1981. Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal valomotor flushes. Am J Obstet Gynecol 139:631–635.

    PubMed  CAS  Google Scholar 

  67. Young RL, Kumar NS, Goldzieher JW. 1990. Management of menopause when estrogen cannot be used. Drugs 40:220–230.

    PubMed  CAS  Google Scholar 

  68. Schiff I, Tuschinsky D, Cramer D. 1980. Oral medroxyprogesterone acetate in the treatment of postmenopausal symtoms. JAMA 244:1443–1445.

    PubMed  CAS  Google Scholar 

  69. Bergmans MGM, Merkus JMWM, Corbey RS, Schellekens LA, Ubach JM. 1987. Effect of bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas 9:227–234.

    PubMed  CAS  Google Scholar 

  70. Longacre TA, Bartow SA. 1986. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 10:382–393.

    PubMed  CAS  Google Scholar 

  71. Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M, Howell A. 1988. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58:163–170.

    PubMed  CAS  Google Scholar 

  72. Anderson TJ, Battersby S, King RJB, McPherson K, Going JJ. 1989. Oral contraceptive use influences resting breast proliferation. Hum Pathol 20:1139–1144.

    PubMed  CAS  Google Scholar 

  73. Bergkvist L, Adami Ho, Person I, et al. 1992. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 130:221–228.

    Google Scholar 

  74. Huggins C, Yang NC. 1962. Induction and extinction of mammary cancer. Science 137:257–262.

    PubMed  CAS  Google Scholar 

  75. Diamond JE, Hollander VP. 1979. Progesterone and breast cancer. Mt Sinai J Med 46:225–235.

    PubMed  CAS  Google Scholar 

  76. Jordan VC, MK, Langan-Fahey S. 1991. Suppression of mouse mammary tumorigenesis by long term tamoxifen therapy. J Natl Cancer Inst 83:492–496.

    PubMed  CAS  Google Scholar 

  77. Kordon E, Lanari C, Meiss R, Elizalde P, Charreau E, Pasqualini CD. 1990. Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate. Breast Cancer Res Treat 33–43.

    Google Scholar 

  78. Hissom JR, Moore MR. 1987. Progestin effects on growth in the human breast cancer cell line T47D. Possible therapeutic implications. Biochem Biophys Res Commun 45:706–711.

    Google Scholar 

  79. Braunsberg H, Coldham NG, Wong W. 1986. Hormonal therapies for breast cancer: can progestogens stimulate growth? Cancer Let 30:213–218.

    CAS  Google Scholar 

  80. The Writing Group for the PEPI trial. 1995. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273:199–208.

    Google Scholar 

  81. Mouridsen HT, Elleman K, Mattsson W. 1979. Therapeuic effect of tamoxifen vs tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 63:171–175.

    PubMed  CAS  Google Scholar 

  82. Gibson DFC, Johnson DA, Langan-Fahey SM, Lababidi MK, Wolberg WH, Jordan VC. 1993. The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model. Breast Cancer Res and Treat 27:283–287.

    CAS  Google Scholar 

  83. Schiff I, Wentworth B, Koos B, Tulchinsky D, Ryan KJ. 1978. Effect of estriol administration on the hypogonadal woman. Fertil Steril 30:278–282.

    PubMed  CAS  Google Scholar 

  84. Mattsson LA, Cullberg G. 1983. Vaginal absorption of two estriol preparations. Asta Obstet Gynecol Scand 62:393–396.

    CAS  Google Scholar 

  85. Heimer GM. 1987. Estriol in the menopause. Acta Obstet Gynecol Scand Suppl 139:23P.

    Google Scholar 

  86. Nachtigall LE. 1994. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 61:178–180.

    PubMed  CAS  Google Scholar 

  87. Mattsson LA, Cullberg G, Eriksson O, Knutsson F. 1989. Vaginal administration of low-dose estradiol - effects on the endometrium and vaginal cytology. Maturitas 11:217–222.

    PubMed  CAS  Google Scholar 

  88. Rymer J, Chapman MG, Fogelman I, Wilson POG. 1994. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 18:127–133.

    PubMed  CAS  Google Scholar 

  89. Love RR, Mazess RB, Barden HS, et al. 1992. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852–856.

    PubMed  CAS  Google Scholar 

  90. Aloia JF, Vaswani A, Yeh JK, et al. 1994. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 120:97–103.

    PubMed  CAS  Google Scholar 

  91. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jorhan VC, Carbone PP, DeMets DL. 1990. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82:1327–1332.

    PubMed  CAS  Google Scholar 

  92. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jorhan VC, Feyzi J, DeMets. 1991. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860–864.

    PubMed  CAS  Google Scholar 

  93. Devor M, Barrett-Connor E, Ranvall M, et al. 1992. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 92:275–282.

    PubMed  CAS  Google Scholar 

  94. Smith DC, Prentice R, Donovan JT, et al. 1975. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164–1167.

    PubMed  CAS  Google Scholar 

  95. Henderson BE, Casagrande JT, Pike MC, et al. 1983. The epidemiology of endometrial cancer in young women. Br J Cancer 47:749–756.

    PubMed  CAS  Google Scholar 

  96. Fornander T, Rutqvist LE, Cedermark B, et al. 1989. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117–120.

    PubMed  CAS  Google Scholar 

  97. Berkowitz JE, Gatewood OM, Goldblum LE, et al. 1990. Hormonal replacement therapy: mammographie manifestations. Radiology 174:199–201.

    PubMed  CAS  Google Scholar 

  98. Kaufman Z, Garstin WI, Hayes R, et al. 1991. The mammographie parenchymal patterns of women on hormonal replacement therapy. Clin Radiol 43:389–392.

    PubMed  CAS  Google Scholar 

  99. Bland KI, Buchanan JB, Weisberg BF, et al. 1980. The effects of exogenous estrogen replacement therapy of the breast: breast cancer risk and mammographie parenchymal patterns. Cancer 45:3027–3033.

    PubMed  CAS  Google Scholar 

  100. Stomper PC, Van Voorhis BJ, Ravnikar VA, et al. 1990. Mammographie changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 174:487–490.

    PubMed  CAS  Google Scholar 

  101. Kelsey JL, Berkowitz GS. 1988. Breast cancer epidemiology. Cancer Res 48:5615–5623.

    PubMed  CAS  Google Scholar 

  102. Harvey EB, Brinton LA. 1985. Second cancer following cancer of the breast in Connecticut, 1935–1982. In Boice JD Jr, Storm HH, Curtis RE, eds. Multiple primary cancers in Connecticut and Denmark. National Cancer Institute Monograph 68. Washington, DC: Government Printing Office, pp. 99–112 (NIH publication no. 85–2714).

    Google Scholar 

  103. Hunt K, Vessey M, McPherson K, Coleman M. 1987. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynecol 94:620–635.

    CAS  Google Scholar 

  104. Palmer JR, Rosenbert L, Clarkey EA, et al. 1991. Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Society. Am J Epidemiol 134:1386–1395.

    PubMed  CAS  Google Scholar 

  105. DuPont WD, Page DL, Roges LW, et al. 1989. Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk. Cancer 643:948–957.

    Google Scholar 

  106. Brownson RC, Blackwell CW, Pearson DK, et al. 1988. Risk of breast cancer relation to cigarette smoking. Arch Intern Med 148:140–144.

    PubMed  CAS  Google Scholar 

  107. Rohan TE, McMichael AJ. 1988. Non-contraceptive exogenous oestrogen therapy and breast cancer. Med J Aust 148:217–221.

    PubMed  CAS  Google Scholar 

  108. Wingo PO, Layde PM, Lee NC, et al. 1987. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 257:209–215.

    PubMed  CAS  Google Scholar 

  109. Buring JE, Hennekens CH, Lipnick RJ. 1987. A prospective cohort study of postmenopausal hormone use and risk of breast cancer in US women. Am J Epidemiol 125:939–947.

    PubMed  CAS  Google Scholar 

  110. Brinton LA, Hoover R, Fraumeni JF Jr. 1986. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 54:825–832.

    PubMed  CAS  Google Scholar 

  111. Nomura AM, Kolonel LN, Hirohata T, et al. 1986. The association of replacement estrogens with breast cancer. Int J Cancer 37:49–53.

    PubMed  CAS  Google Scholar 

  112. Horwitz RI, Stewart KR. 1984. Effect of clinical features on the association of estrogens and breast cancer. Am J Med 76:192–198.

    PubMed  CAS  Google Scholar 

  113. Kaufman DW, Miller DR, Rosenberg L, et al. 1984. Noncontraceptive estrogen use and the risk of breast cancer. JAMA 252:63–67.

    PubMed  CAS  Google Scholar 

  114. Hiatt RA, Bawol R, Friedman GD, et al. 1984. Exogenous estrogen and breast cancer after bilateral oophorectomy. Cancer 54:139–144.

    PubMed  CAS  Google Scholar 

  115. Sherman B, Wallace R, Bean J. 1983. Estrogen use and breast cancer: interaction with body mass. Cancer 51:1527–1531.

    PubMed  CAS  Google Scholar 

  116. Gambrell RD, Maier RC, Sanders BI. 1983. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 62:435–443.

    PubMed  Google Scholar 

  117. Kelsey JL, Fischer DB, Holford TR, et al. 1981. Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst 67:327–333.

    PubMed  CAS  Google Scholar 

  118. Kaufman DW, Palmer JR, deMouzon J, et al. 1991. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 134:1375–1385.

    PubMed  CAS  Google Scholar 

  119. Colditz GA, Stampfer MJ, Willett WC, et al. 1990. Prospective study of estrogen replacement therapy and risk of breast cancer in pmp women. JAMA 264:2648–2653.

    PubMed  CAS  Google Scholar 

  120. Bergkvist L, Adami HO, Person I, et al. 1989. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321:293–297.

    PubMed  CAS  Google Scholar 

  121. Mills PK, Beeson WL, Phillips RL, et al. 1989. Prospective study of exogenous hormone use and breast cancer in Seventh-Day Adventists. Cancer 64:591–597.

    PubMed  CAS  Google Scholar 

  122. Ewertz M. 1988. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 42:832–838.

    PubMed  CAS  Google Scholar 

  123. Hulka BS, Chambless LE, Deubner DC, et al. 1982. Breast cancer and estrogen replacement therapy. Am J Obstet Gynecol 143:638–644.

    PubMed  CAS  Google Scholar 

  124. Thomas DB, Persing JP, Hutchinson WB. 1982. Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases. J Natl Cancer Inst 69:1017–1025.

    PubMed  CAS  Google Scholar 

  125. Hoover R, Glass A, Finkle WD, et al. 1981. Conjugated estrogens and breast cancer risk in women. J Natl Cancer Inst 67:815–820.

    PubMed  CAS  Google Scholar 

  126. Ross RK, Paganini-Hill, Gerkins VR, et al. 1980. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 243:1635–1639.

    PubMed  CAS  Google Scholar 

  127. DuPont WD, Page DL. 1991. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151:67–72.

    PubMed  CAS  Google Scholar 

  128. Steinberg KK, Thacker SB, Smith SJ, et al. 1991. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985–1990.

    PubMed  CAS  Google Scholar 

  129. Armstrong BK. 1988. Oestrogen therapy after the menopause -- boon or bane? Med J Aust 148:213–214.

    PubMed  CAS  Google Scholar 

  130. Grady D, Ernster V. 1991. Invited commentary: does postmenopausal hormone therapy cause breast cancer? Am J Epidemiol 134:1396–1400.

    Google Scholar 

  131. Sillero-Arenas M, Delgado-Rodriguez M, Rodrigues-Canteras R, et al. 1992. Menopausal hormone replacement therapy and breast cancer; a meta-analysis. Obstet Gynecol 79:286–294.

    PubMed  CAS  Google Scholar 

  132. Colditz GA, Egan KM, Stampfer MJ. 1993. Hormone replacement therapy and risk of breast cancer; results from epidemilogic studies. Am J Obstet Gynecol 168:1473–1480.

    PubMed  CAS  Google Scholar 

  133. Henrich JB. 1992. The postmenopausal estrogen/breast cancer controversy. JAMA 268:1900–1902.

    PubMed  CAS  Google Scholar 

  134. Thijssen JHH, Van Landeghem AAJ, Poortman J. 1986. Uptake and concentration of steroid hormones in mammary tissues. Ann N Y Acad Sci 464:106–116.

    PubMed  CAS  Google Scholar 

  135. Nayfield SG, Karp JE, Ford LG, et al. 1991. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450–1458.

    PubMed  CAS  Google Scholar 

  136. Adami HO, Malker B, Holmberg L, et al. 1986. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559–563.

    PubMed  CAS  Google Scholar 

  137. Adami HO, Holmberg L, Malker B, et al. 1987. Letter. N Engl J Med 316:752.

    Google Scholar 

  138. Henderson BE, Paganini-Hill A, Ross RK. 1991. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151:75–78.

    PubMed  CAS  Google Scholar 

  139. Criqui MH, Suarez L, Barrett-Connor E, et al. 1988. Postmenopausal estrogen use and mortality. Am J Epidemiol 128:606–614.

    PubMed  CAS  Google Scholar 

  140. Gambrell DR. 1984. Proposal to decrease the risk and improve the prognosis in breast cancer. Am J Obstet Gynecol 150:119–128.

    PubMed  Google Scholar 

  141. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. 1995. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589–1593.

    PubMed  CAS  Google Scholar 

  142. Dao TL, Sinha DI, Nemoto T, Patel J. 1982. Effect of estrogen and progesterone on cellular replication of human breast tumors. Cancer Res 42:359–362.

    PubMed  CAS  Google Scholar 

  143. Dhodapkar MV, Ingle JN, Ahmann DL. 1995. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 75:43–46.

    PubMed  CAS  Google Scholar 

  144. Lippman M, Bolan G, Huff K. 1976. The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long-term tissue culture. Cancer Res 36:4595–4601.

    PubMed  CAS  Google Scholar 

  145. Stoll BA. 1967. Effect of Lyndiol, an oral contraceptive, on breast cancer. Br Med J 1:150–153.

    PubMed  CAS  Google Scholar 

  146. Wile AG, Opfell DA, Hoda AC. 1991. Hormone replacement therapy does not affect breast cancer outcome. Proc Am Soc Clin Oncol 10:58.

    Google Scholar 

  147. Wile AG, Opfell RW, Margileth DA. 1993. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 165:372–375.

    PubMed  CAS  Google Scholar 

  148. Eden JA, Bush T, Nand S, Wren BG. 1995. The Royal Hospital for Women Breast Cancer Study — a case–controlled study of combined continuous hormone replacement therapy amongst women with a personal history of breast cancer. Menopause 2:67–72.

    Google Scholar 

  149. Theriault RV, Sellin RV. 1994. Estrogen-replacement therapy in younger women with breast cancer. Monogr Natl Cancer Inst (16):149–152.

    PubMed  Google Scholar 

Download references

Authors
  1. Melody A. Cobleigh
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA

    Kenneth A. Foon M.D.

  2. College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont, USA

    Hyman B. Muss M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cobleigh, M.A. (1998). Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors. In: Foon, K.A., Muss, H.B. (eds) Biological and Hormonal Therapies of Cancer. Cancer Treatment and Research, vol 94. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6189-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6189-7_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7837-2

  • Online ISBN: 978-1-4615-6189-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation